Elutia Inc. (ELUT)vsStryker Corporation (SYK)
ELUT
Elutia Inc.
$0.85
-3.52%
HEALTHCARE · Cap: $38.95M
SYK
Stryker Corporation
$337.43
+0.47%
HEALTHCARE · Cap: $128.87B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 207326% more annual revenue ($25.84B vs $12.46M). ELUT leads profitability with a 400.2% profit margin vs 14.4%. SYK earns a higher WallStSmart Score of 63/100 (C+).
ELUT
Hold41
out of 100
Grade: D
SYK
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.2%
Fair Value
$0.94
Current Price
$0.85
$0.09 discount
Margin of Safety
-47.2%
Fair Value
$228.91
Current Price
$337.43
$108.52 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 221 in profit
Keeps 400 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Reasonable price relative to book value
Large-cap with strong market position
Strong operational efficiency at 27.0%
Earnings expanding 44.1% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Distress zone — elevated risk
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ELUT
The strongest argument for ELUT centers on Return on Equity, Profit Margin, Debt/Equity. Profitability is solid with margins at 400.2% and operating margin at -184.4%.
Bull Case : SYK
The strongest argument for SYK centers on Market Cap, Operating Margin, EPS Growth.
Bear Case : ELUT
The primary concerns for ELUT are EPS Growth, Market Cap, Free Cash Flow.
Bear Case : SYK
The primary concerns for SYK are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
ELUT profiles as a mature stock while SYK is a value play — different risk/reward profiles.
ELUT carries more volatility with a beta of 0.88 — expect wider price swings.
SYK is growing revenue faster at 9.4% — sustainability is the question.
SYK generates stronger free cash flow (415M), providing more financial flexibility.
Bottom Line
SYK scores higher overall (63/100 vs 41/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Elutia Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Elutia Inc., a commercial-stage company, engages in developing and commercializing drug-eluting biomatrix technology to enhance surgical outcomes. The company is headquartered in Silver Spring, Maryland.
Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?